Tenaya Therapeutics IncNASDAQ:TNYA
- LAST PRICE2.2950
- TODAY'S CHANGE (%)0.1350 (6.2500%)
- Bid / Lots2.2900/ 12
- Ask / Lots2.3000/ 50
- Open / Previous Close2.1600 / 2.1600
- Day Range
- 52 Week Range
- Volume1,203,271
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TNYA |
|---|---|---|
| 09:32 ET | 76996 | 2.125 |
| 09:33 ET | 18757 | 2.126 |
| 09:35 ET | 6501 | 2.1188 |
| 09:37 ET | 85248 | 2.115 |
| 09:39 ET | 16281 | 2.1088 |
| 09:42 ET | 14526 | 2.114 |
| 09:44 ET | 4699 | 2.12 |
| 09:46 ET | 12167 | 2.1301 |
| 09:48 ET | 5289 | 2.13 |
| 09:50 ET | 8483 | 2.1499 |
| 09:51 ET | 5700 | 2.136038 |
| 09:53 ET | 9059 | 2.135 |
| 09:55 ET | 19680 | 2.16 |
| 09:57 ET | 17017 | 2.16 |
| 10:00 ET | 14225 | 2.169 |
| 10:02 ET | 25698 | 2.15 |
| 10:04 ET | 24688 | 2.1715 |
| 10:06 ET | 7642 | 2.17 |
| 10:08 ET | 9509 | 2.185 |
| 10:09 ET | 28764 | 2.2092 |
| 10:11 ET | 13617 | 2.19 |
| 10:13 ET | 2728 | 2.195 |
| 10:15 ET | 4755 | 2.2 |
| 10:18 ET | 6821 | 2.205 |
| 10:20 ET | 18601 | 2.2 |
| 10:22 ET | 16964 | 2.2 |
| 10:24 ET | 13831 | 2.195 |
| 10:26 ET | 16388 | 2.2 |
| 10:27 ET | 9312 | 2.195 |
| 10:29 ET | 14480 | 2.175 |
| 10:31 ET | 17604 | 2.1799 |
| 10:33 ET | 4535 | 2.18 |
| 10:36 ET | 7930 | 2.1985 |
| 10:38 ET | 6003 | 2.195 |
| 10:40 ET | 8859 | 2.21 |
| 10:42 ET | 3354 | 2.205 |
| 10:44 ET | 6511 | 2.215 |
| 10:45 ET | 8802 | 2.225 |
| 10:47 ET | 2177 | 2.22 |
| 10:49 ET | 43015 | 2.2003 |
| 10:51 ET | 16339 | 2.2 |
| 10:54 ET | 8546 | 2.2 |
| 10:56 ET | 12791 | 2.2 |
| 10:58 ET | 20567 | 2.2 |
| 11:00 ET | 6619 | 2.2 |
| 11:02 ET | 4776 | 2.2 |
| 11:03 ET | 2436 | 2.2085 |
| 11:05 ET | 7548 | 2.2 |
| 11:07 ET | 2429 | 2.2 |
| 11:09 ET | 17525 | 2.225 |
| 11:12 ET | 2272 | 2.225 |
| 11:14 ET | 16030 | 2.2315 |
| 11:16 ET | 3273 | 2.24 |
| 11:18 ET | 16794 | 2.225 |
| 11:20 ET | 21169 | 2.235 |
| 11:21 ET | 17956 | 2.2399 |
| 11:23 ET | 35282 | 2.2583 |
| 11:25 ET | 1830 | 2.26 |
| 11:27 ET | 12073 | 2.26 |
| 11:30 ET | 2084 | 2.2501 |
| 11:32 ET | 14335 | 2.26 |
| 11:34 ET | 6649 | 2.265 |
| 11:36 ET | 12614 | 2.265 |
| 11:38 ET | 52836 | 2.2988 |
| 11:39 ET | 54086 | 2.295 |
| 11:41 ET | 21593 | 2.295 |
| 11:43 ET | 1308 | 2.295 |
Nov 19, 2024
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4), from 8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 7, 2024
DJ Tenaya Therapeutics Is Maintained at Buy by Chardan Capital, from 9:26AM ET on Thursday Nov 07, 2024 by Dow Jones
9:26AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow JonesPress Release: Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tenaya Therapeutics Inc | 171.1M | -1.6x | --- |
Greenwich Lifesciences Inc | 170.5M | -16.5x | --- |
Kyverna Therapeutics Inc | 172.2M | -1.7x | --- |
Nkarta Inc | 172.2M | -1.3x | --- |
Galectin Therapeutics Inc | 169.4M | -3.8x | --- |
Inozyme Pharma Inc | 172.8M | -1.7x | --- |
Company Information
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Contact Information
- Headquarters
- 171 Oyster Point Blvd., Suite 500SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 415-865-2066
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Goeddel
- Chief Executive Officer, Director
- Faraz Ali
- Chief Medical Officer
- Whittemore Tingley
- Independent Director
- Amy Burroughs
- Independent Director
- June Lee
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $171.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 79.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.37 |
EPS | $-1.44 |
Book Value | $2.04 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
